WO1999050295A3 - Agouti-related protein analogs and methods of use - Google Patents

Agouti-related protein analogs and methods of use Download PDF

Info

Publication number
WO1999050295A3
WO1999050295A3 PCT/US1999/006968 US9906968W WO9950295A3 WO 1999050295 A3 WO1999050295 A3 WO 1999050295A3 US 9906968 W US9906968 W US 9906968W WO 9950295 A3 WO9950295 A3 WO 9950295A3
Authority
WO
WIPO (PCT)
Prior art keywords
agouti
methods
related protein
agrp
analogues
Prior art date
Application number
PCT/US1999/006968
Other languages
French (fr)
Other versions
WO1999050295A2 (en
Inventor
Darren A Thompson
Jill Wilken
Ira Gantz
Stephen B H Kent
Original Assignee
Gryphon Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Sciences filed Critical Gryphon Sciences
Priority to AU39644/99A priority Critical patent/AU3964499A/en
Publication of WO1999050295A2 publication Critical patent/WO1999050295A2/en
Publication of WO1999050295A3 publication Critical patent/WO1999050295A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to Agouti-related protein (AGRP) analogues and methods of use. The invention is exemplified by chemical synthesis and detectable labeling of AGRP analogues, and their novel exploitation in a variety of different assays and screens. The inventions find use, for example, in drug discovery and diagnostics related to feeding disorders including wasting syndromes, obesity, and other disorders related to hypothalamic control of feeding.
PCT/US1999/006968 1998-03-30 1999-03-30 Agouti-related protein analogs and methods of use WO1999050295A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39644/99A AU3964499A (en) 1998-03-30 1999-03-30 Agouti-related protein analogs and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7995798P 1998-03-30 1998-03-30
US60/079,957 1998-03-30

Publications (2)

Publication Number Publication Date
WO1999050295A2 WO1999050295A2 (en) 1999-10-07
WO1999050295A3 true WO1999050295A3 (en) 1999-11-18

Family

ID=22153903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006968 WO1999050295A2 (en) 1998-03-30 1999-03-30 Agouti-related protein analogs and methods of use

Country Status (2)

Country Link
AU (1) AU3964499A (en)
WO (1) WO1999050295A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030808A1 (en) * 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
EP1125579A3 (en) 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
WO2001085930A2 (en) * 2000-05-09 2001-11-15 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
CA2477614A1 (en) * 2002-03-05 2003-09-18 Merck & Co., Inc. Biomarker for efficacy of appetite suppressant drugs
BRPI0510095A (en) 2004-04-20 2007-10-16 Transtech Pharma Inc substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
US20110160128A1 (en) * 2008-03-28 2011-06-30 Qingyu Wu Corin for Treating Obesity and Diabetes
WO2010025142A1 (en) 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043412A1 (en) * 1996-05-10 1997-11-20 Amgen Inc. Novel agouti-related gene
WO1997047316A1 (en) * 1996-06-10 1997-12-18 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043412A1 (en) * 1996-05-10 1997-11-20 Amgen Inc. Novel agouti-related gene
WO1997047316A1 (en) * 1996-06-10 1997-12-18 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HASKELL-LUEVANO C ET AL: "DISCOVERY OF PROTOTYPE PEPTIDOMIMETIC AGONISTS AT THE HUMAN MELANOCORTIN RECEPTORS MC1R AND MC4R", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 4, 1997, pages 2133 - 2139, XP002910702, ISSN: 0022-2623 *
YANG ET AL.: "Characterization of Agouti-related protein binding to melanocortin receptors", MOLECULAR ENDOCRINOLOGY, vol. 13, no. 1, January 1999 (1999-01-01), pages 148 - 155, XP002114621 *

Also Published As

Publication number Publication date
WO1999050295A2 (en) 1999-10-07
AU3964499A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
ZA992877B (en) Process for the preparation of hyndrocarbons from synthesis gas.
IT1234978B (en) TWO-STAGE CEMENTITIOUS MIXTURE, PARTICULARLY SUITABLE FOR ORTHOPEDIC USES.
ZA983503B (en) Low temperature process for producing synthesis gas.
AU578312B2 (en) Recovering methane enriched gas from syngas by psa.
WO1999050295A3 (en) Agouti-related protein analogs and methods of use
ZA995566B (en) Ceramic membrane for endothermic reactions.
WO2003006996A3 (en) Natural ligand of gpcr chemr23 and uses thereof
IL131155A (en) Assay for the measurement of dna synthesis rates
MXPA03010880A (en) Calorically dense liquid oral supplement.
ATE198047T1 (en) MEDICAL PREPARATION CONTAINING A LIPOPHILIC NOBLE GAS
GB9928450D0 (en) IGF-1 receptor interacting proteins (IIPs), genes coding therefor and uses thereof
WO2002097031A3 (en) Molecules for diagnostics and therapeutics
EP1983059A3 (en) Reaction mixtures for producing dipeptides
CA2165366A1 (en) Cryogenic Rectification System for Fluorine Compound Recovery
DE69416359D1 (en) Chemical cleaning through partial condensation for semiconductor production
WO2003004681A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 20, the encoded polypeptides and methods based thereon
IL138658A0 (en) Chimeric protein
WO1999029308A3 (en) Method for combating obesity
DE60105236D1 (en) Purification method for a liquid reaction mixture from the epoxidation of 1,5,9-cyclododecatriene
AU2002236908A1 (en) Systems, methods, and computer program products for determining the parameters for chemical synthesis and for supplying the reagents, equipment and/or chemicals synthesized thereby
WO2000005243A3 (en) Resin derivatization method and uses thereof
AU1849295A (en) Mixing assembly for gaseous flows at different temperatures,in particular for heterogeneous exothermic synthesis reactors
EP1129105A4 (en) Dna molecules encoding the melanocortin 4 receptor protein from rhesus monkey
WO2004003165A3 (en) Novel polynucleotide and polypeptide sequences and uses thereof
WO2001062927A3 (en) Polypeptides and corresponding polynucleotides for diagnostics and therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase